TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00926744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
Study: NCT01662466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone cream (0.5mg per gram)
Description: Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: DHEA
Description: DHEA 25mg tid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: DHEA 25mg tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Carrier cream without added testosterone in the identical type of pump
Study: NCT00855283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN NEO
Description: 20 mg Neostigmine via intranasal and sublingual administration
Study: NCT05941143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness-based intervention
Description: 8 weekly group 2-hour sessions program adapted from mindfulness-based stress reduction and mindfulness-based cognitive therapy protocols. It was specifically tailored to older adults.
Study: NCT03005743

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image based Brachytherapy
Description: MRI based BT prescription will be in accordance to the GEC-ESTRO guidelines \[Intention will be to treat the whole cervix and the remaining residual tumour tissue at the primary site at the time of BT (high risk-clinical target volume) to a dose level analogue to the dose level previously prescribed for point-A\]

Intervention type: RADIATION
Group type: OTHER
Intervention: Conventional Radiograph based Brachytherapy
Description: The standard conventional radiography based prescription will be according to Manchester system Point A and bladder \& rectum ICRU point dose constraints
Study: NCT00819598

Intervention type: PROCEDURE
Intervention: BLOOD PRESSURE MEASURMENT
Description: Blood pressures using Doppler and oscillometric methods will be obtained at each limb and on one toe from each foot.

Intervention type: PROCEDURE
Intervention: BLOOD PRESSURE MEASUREMENT
Description: Blood pressure measurements will be taken at each limb (arm and ankle) with Doppler and oscillometric based methods.
Study: NCT03361969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estetrol
Description: estetrol formulated in tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo tablets
Study: NCT04079413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP40071
Description: GP40071, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid® Penfill®
Description: NovoRapid® Penfill®, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
Study: NCT02513498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04089566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nusinersen
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered as specified in the treatment arm
Study: NCT02396420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere Microspheres
Study: NCT04362072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: 25 milligram (mg) tablet
Study: NCT02515383

Intervention type: OTHER
Intervention: Interview
Description: Complete cognitive debriefing interview

Intervention type: OTHER
Intervention: Interview
Description: Complete cognitive debriefing interview

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete MDASI questionnaire

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete MDASI questionnaire
Study: NCT02499653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videos
Study: NCT02076893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: The active comparator arm will receive gabapentin as per dosing specifics listed in the study arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Both study arms will receive tramadol per dosing details listed in the study arm descriptions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: Both study arms will receive tramadol per dosing details listed in the study arm descriptions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Both study arms will receive as needed (PRN) ibuprofen to take home.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Both study arms will receive as needed (PRN) ibuprofen to take home.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simple syrup suspension
Study: NCT01623401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: TR-701 FA 200 mg once daily
Study: NCT01353690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMDC
Description: Cell Treatment
Study: NCT01860040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Alkylating antineoplastic agent (Chemotherapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Alkylating antineoplastic agent (Chemotherapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Antimetabolite antineoplastic agent (Chemotherapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Antimetabolite antineoplastic agent (Chemotherapy)
Study: NCT00757458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EDTA without re-filling
Description: Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Propofol syringe re-filling with propofol containing EDTA
Description: Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Target controlled infusion of propofol without EDTA
Description: Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Re-filling of syringe with propofol without EDTA
Description: Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
Study: NCT01669174

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338
Description: BYM338
Study: NCT01190410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: certolizumab pegol
Description: 400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: certolizumab pegol
Description: 200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to \< 40 kg
Study: NCT03654716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine belongs to the category of chemotherapy called antimetabolites. Antimetabolites are very similar to normal substances within the cell. When the cells incorporate these substances into the cellular metabolism, they are unable to divide
Study: NCT01243216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound examination of the lumbar spine. The level of the lumbar interspace will be determined by the oblique/sagittal method. The transverse method will be used to determine the best lumbar interspace and the distance from the skin to the target (epidural space or intrathecal space)
Study: NCT00798668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Supplements
Description: Liquid supplement that provides 12.5% of the subjects total energy requirement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Supplements
Description: Liquid supplement that provides 12.5% of the subjects total energy requirement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solid Supplement
Description: Solid supplement that provides 12.5% of the subjects total energy requirement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solid Supplement
Description: Solid supplement that provides 12.5% of the subjects total energy requirement.
Study: NCT02905981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fer-In-Sol
Description: Fer-In-Sol is an over-the-counter oral iron supplement. It will be administered during Period 1 at a dose of 3 mg/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shohl's solution
Description: Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shohl's solution
Description: Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shohl's solution
Description: Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.
Study: NCT01063270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin & Rifampin
Description: Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin + Rifampin along with NdYag Laser treatment
Description: Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.
Study: NCT02648854

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
Description: administered CKD-395 0.5/1000mg 1T to oral (fasting condition)

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
Description: administered CKD-395 0.5/1000mg 1T to oral (fasting condition)

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
Description: administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
Description: administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
Study: NCT03809767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1003 monoclonal antibody
Description: CS1003 will be administered intravenously every 3 weeks.
Study: NCT04149782

Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.

Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
Study: NCT01802736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational intervention counselling plus SPP

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational intervention counselling plus SPP
Study: NCT03189667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vessel preparation with angioplasty
Description: Vessel preparation with Pre dilatation:~* All lesions to be predilated with high pressure balloons until waist is obliterated.~* At least two minutes dilatation.~* Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~* Multiple lesions:~  * To be treated with single balloon if possible.~ * To be treated with multiple inflation if cannot be covered with single balloon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vessel preparation with angioplasty
Description: Vessel preparation with Pre dilatation:~* All lesions to be predilated with high pressure balloons until waist is obliterated.~* At least two minutes dilatation.~* Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~* Multiple lesions:~  * To be treated with single balloon if possible.~ * To be treated with multiple inflation if cannot be covered with single balloon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain balloon angioplasty
Description: Plain balloon angioplasty~* Vessel treatment with additional Plain balloon angioplasty:~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to predilation balloon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug coated balloon angioplasty
Description: Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to the predilation balloon.~* New drug coated balloon will be required for each lesion.
Study: NCT05039814

Intervention type: OTHER
Intervention: postoperative acute kidney injury
Description: patients suffered postoperative acute kidney injury

Intervention type: OTHER
Intervention: none postoperative acute kidney injury
Description: patients did not suffered postoperative acute kidney injury
Study: NCT03915431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NCS-01
Description: single infusion

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: NCS-01
Description: single infusion
Study: NCT03549884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Description: Cord clamping will be performed after 60 seconds of life in infants delivered by cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early cord clamping
Description: Cord clamping will be performed within 10 seconds of life in infants delivered by cesarean section
Study: NCT04140253

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) with lumbopelvic stabilization
Description: Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.~1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions~2. Training of pelvic floor muscles in different position~3. Training of pelvic floor muscles with lumbopelvic stabilization~Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) with lumbopelvic stabilization
Description: Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.~1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions~2. Training of pelvic floor muscles in different position~3. Training of pelvic floor muscles with lumbopelvic stabilization~Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist.
Study: NCT03113214

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 1
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
Study: NCT00461292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (200U)
Description: botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection \> Week 12; injections into detrusor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (300U)
Description: botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection \> Week 12; injections into detrusor

Intervention type: OTHER
Group type: OTHER
Intervention: Normal saline (Placebo); botulinum toxin Type A (200U)
Description: Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection \> 12 weeks; injections into detrusor

Intervention type: OTHER
Group type: OTHER
Intervention: Normal saline (Placebo); botulinum toxin Type A (300U)
Description: Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection \> Week 12; injections into detrusor
Study: NCT02759185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC cannabis
Description: Three weeks of smoking cannabis containing more THC than CBD with amount smoked limited to no more than 1.8 g per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High CBD cannabis
Description: Three weeks of smoking cannabis containing more CBD than THC with amount smoked limited to no more than 1.8 g per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD cannabis
Description: Three weeks of smoking cannabis containing equal amounts of THC and CBD with smoking limited to no more than 1.8 g per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cannabis
Description: Three weeks of smoking cannabis with low levels of THC and CBD with smoking limited to no more than 1.8 per day.
Study: NCT04444284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine MV-012-968 (Dosage 1)
Description: Single dose administered intranasally on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine MV-012-968 (Dosage 2)
Description: Single dose administered intranasally on Day 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered intranasally on Day 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered intranasally on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine MV-012-968 (Dosage 3)
Description: Single dose administered intranasally on Day 1